Newbridge Financial Services Group’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-6,000
Closed -$7.68K – 1371
2025
Q3
$7.68K Hold
6,000
– – ﹤0.01% 948
2025
Q2
$7.44K Hold
6,000
– – ﹤0.01% 952
2025
Q1
$7.08K Hold
6,000
– – ﹤0.01% 744
2024
Q4
$11K Hold
6,000
– – ﹤0.01% 715
2024
Q3
$10.2K Hold
6,000
– – ﹤0.01% 427
2024
Q2
$8.22K Buy
+6,000
New +$12.1K ﹤0.01% 746
2022
Q2
– Sell
-957
Closed -$9K – 1475
2022
Q1
$9K Buy
957
+558
+140% +$6.42K ﹤0.01% 968
2021
Q4
$8K Buy
+399
New +$9.63K ﹤0.01% 973

Other funds holding PACB

Newbridge Financial Services Group's PACB Position: Q4 2025 in Review

Newbridge Financial Services Group sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 6,000 shares — an estimated $7.68K sold.

Newbridge Financial Services Group first reported a position in PACB in Q4 2021 and held it in 8 quarters. The position peaked at $11K in Q4 2024. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • Newbridge Financial Services Group reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 6,000 Pacific Biosciences shares in Q4 2025, an estimated $7.68K.
  • Newbridge Financial Services Group first reported a position in Pacific Biosciences in Q4 2021 and held it in 8 quarters.
  • Newbridge Financial Services Group's Pacific Biosciences position peaked at $11K in Q4 2024.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Newbridge Financial Services Group's 13F filing for Q4 2025, filed 21 Jan 2026.